Status:
COMPLETED
A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients
Lead Sponsor:
Novartis
Conditions:
Hypertension
Diabetes
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
To evaluate the blood pressure lowering effect and safety of aliskiren used in combination with valsartan/hydrochlorothiazide in diabetic patients with essential hypertension, not adequately responsiv...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Patients with essential hypertension
- Patients with a documented diagnosis of Type 1 or Type 2 diabetes mellitus.
- Patients who are eligible and able to participate in the study
- Exclusion Criteria
- Severe hypertension
- Uncontrolled diabetes type I and II
- History or evidence of a secondary form of hypertension
- History of Hypertensive encephalopathy or cerebrovascular accident.
- Other protocol-defined exclusion criteria may apply.
Exclusion
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
End Date :
May 1 2007
Estimated Enrollment :
336 Patients enrolled
Trial Details
Trial ID
NCT00219102
Start Date
June 1 2005
End Date
May 1 2007
Last Update
February 11 2020
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigative Site
Salisbury, North Carolina, United States, 28144
2
Investigative Site
Kortrijk, Belgium
3
Investigative Site
Bucharest, Romania
4
Investigative Site
Madrid, Spain